(Q33609283)

28 July 2017

1 reference

title

A risk-benefit assessment of HIV protease inhibitors (English)

1 reference

28 July 2017

G J Moyle

1

1 reference

PubMed ID

10230580

28 July 2017

B G Gazzard

series ordinal

2

1 reference

28 July 2017

1 April 1999

1 reference

28 July 2017

1 reference

28 July 2017

20

1 reference

28 July 2017

4

1 reference

28 July 2017

299-321

1 reference

https://scigraph.springernature.com/pub.10.2165/00002018-199920040-00002

28 July 2017

0 references

cites work

Clinical efficacy of monotherapy with stavudine compared with zidovudine in HIV-infected, zidovudine-experienced patients. A randomized, double-blind, controlled trial. Bristol-Myers Squibb Stavudine/019 Study Group

1 reference

12 December 2020

Detection of three distinct patterns of T helper cell dysfunction in asymptomatic, human immunodeficiency virus-seropositive patients. Independence of CD4+ cell numbers and clinical staging

1 reference

12 December 2020

A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors

1 reference

12 December 2020

Renal dysfunction in a human immunodeficiency virus-infected patient who was treated with indinavir

1 reference

12 December 2020

Antiretroviral therapy for HIV infection. A knowledge-based approach to drug selection and use.

1 reference

12 December 2020

Safety profile of soft gelatin formulation of saquinavir in combination with nucleosides in a broad patient population. NV15182 Study Team.

1 reference

12 December 2020

Improved compliance measures: applications in an ambulatory hypertensive drug trial

1 reference

12 December 2020

Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance.

1 reference

12 December 2020

Peripheral neuropathy with nucleoside antiretrovirals: risk factors, incidence and management

1 reference

12 December 2020

Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases

1 reference

12 December 2020

Long-lasting remission of cytomegalovirus retinitis without maintenance therapy in human immunodeficiency virus-infected patients.

1 reference

12 December 2020

Studies in subjects with long-term nonprogressive human immunodeficiency virus infection

1 reference

12 December 2020

Indinavir-induced renal failure

1 reference

12 December 2020

Indinavir sulfate renal toxicity in a pediatric hemophiliac with HIV infection

1 reference

12 December 2020

British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals. BHIVA Guidelines Co-ordinating Committee

1 reference

12 December 2020

A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team

1 reference

12 December 2020

A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team

1 reference

12 December 2020

Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease

1 reference

12 December 2020

Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy

1 reference

12 December 2020

Quality of life outcomes of combination zalcitabine-zidovudine, saquinavir-zidovudine, and saquinavir-zalcitabine-zidovudine therapy for HIV-infected adults with CD4 cell counts between 50 and 350 per cubic millimeter. PISCES (SV14604) Study Group.

1 reference

12 December 2020

Indinavir nephropathy

1 reference

12 December 2020

Zidovudine in persons with asymptomatic HIV infection and CD4+ cell counts greater than 400 per cubic millimeter. The European-Australian Collaborative Group

1 reference

12 December 2020

Lamivudine plus zidovudine compared with zalcitabine plus zidovudine in patients with HIV infection. A randomized, double-blind, placebo-controlled trial. North American HIV Working Party

1 reference

12 December 2020

Visceral abdominal-fat accumulation associated with use of indinavir

1 reference

12 December 2020

Hypertrophy of the breasts in a patient treated with indinavir

1 reference

12 December 2020

1998 revision to the British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals. BHIVA Guidelines Writing Committee

1 reference

12 December 2020

Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: the CAESAR trial

1 reference

12 December 2020

A preliminary evaluation of nelfinavir mesylate, an inhibitor of human immunodeficiency virus (HIV)-1 protease, to treat HIV infection

1 reference

12 December 2020

Risk factors for ritonavir intolerance and outcome after change to indinavir

1 reference

12 December 2020

Discontinuation of Mycobacterium avium complex prophylaxis in patients with a rise in CD4 cell count following highly active antiretroviral therapy

1 reference

12 December 2020

Resolution of intractable molluscum contagiosum in a human immunodeficiency virus-infected patient after institution of antiretroviral therapy with ritonavir

1 reference

12 December 2020

Increased bleeding in HIV-positive haemophiliacs treated with antiretroviral protease inhibitors

1 reference

12 December 2020

1 reference

12 December 2020

Severe premature coronary artery disease with protease inhibitors

1 reference

12 December 2020

Viral resistance patterns selected by antiretroviral drugs and their potential to guide treatment choice

1 reference

12 December 2020

Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel

1 reference

12 December 2020

Evaluation of the quality of life associated with zidovudine treatment in asymptomatic human immunodeficiency virus infection. The AIDS Clinical Trials Group

1 reference

12 December 2020

"Buffalo hump" in men with HIV-1 infection.

1 reference

12 December 2020

Patient compliance and drug failure in protease inhibitor monotherapy

1 reference

12 December 2020

Indinavir-associated lipodystrophy.

1 reference

12 December 2020

Regression of AIDS-related Kaposi's sarcoma following treatment with an HIV-1 protease inhibitor

1 reference

12 December 2020

HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy

1 reference

12 December 2020

Acute hepatitis in HIV-infected patients during ritonavir treatment

1 reference

12 December 2020

Severe allergic reaction after repeated exposure to indinavir

1 reference

12 December 2020

How immune-based interventions can change HIV therapy

1 reference

12 December 2020

Association between CCR5 genotype and the clinical course of HIV-1 infection

1 reference

12 December 2020

Predicting clinical progression or death in subjects with early-stage human immunodeficiency virus (HIV) infection: a comparative analysis of quantification of HIV RNA, soluble tumor necrosis factor type II receptors, neopterin, and beta2-microglobu

1 reference

12 December 2020

Maintenance therapy after quadruple induction therapy in HIV-1 infected individuals: Amsterdam Duration of Antiretroviral Medication (ADAM) study

1 reference

12 December 2020

Safety, pharmacokinetics, and antiretroviral activity of the potent, specific human immunodeficiency virus protease inhibitor nelfinavir: results of a phase I/II trial and extended follow-up in patients infected with human immunodeficiency virus

1 reference

12 December 2020

Serum levels of human immunodeficiency virus type 1 (HIV-1) RNA after seroconversion: a predictor of long-term mortality in HIV infection

1 reference

12 December 2020

Indinavir nephrolithiasis in warm climates

1 reference

12 December 2020

Human immunodeficiency virus disease: changing patterns of intraocular inflammation

1 reference

12 December 2020

Is the combination of hepatitis and indinavir potentially dangerous?

1 reference

12 December 2020

Concorde: MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection. Concorde Coordinating Committee

1 reference

12 December 2020

Marked hypertriglyceridaemia associated with ritonavir therapy

1 reference

12 December 2020

Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy

1 reference

12 December 2020

Fever, erythroderma, abdominal pain, and renal failure following initiation of indinavir therapy

1 reference

12 December 2020

The role of combinations of HIV protease inhibitors in the management of persons with HIV infection.

1 reference

12 December 2020

Hypersensitivity reactions during antiretroviral regimens with protease inhibitors

1 reference

12 December 2020

Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection

1 reference

12 December 2020

Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy

1 reference

12 December 2020

Focal mycobacterial lymphadenitis following initiation of protease-inhibitor therapy in patients with advanced HIV-1 disease.

1 reference

12 December 2020

Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Delta Coordinating Committee

1 reference

12 December 2020

Gynecomastia during indinavir antiretroviral therapy in HIV infection

1 reference

12 December 2020

HIV infection induces changes in CD4+ T-cell phenotype and depletions within the CD4+ T-cell repertoire that are not immediately restored by antiviral or immune-based therapies

1 reference

12 December 2020

Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. The Advanced HIV Disease Ritonavir Study Group

1 reference

12 December 2020

Combination antiretroviral therapy in HIV infection. An economic perspective

1 reference

12 December 2020

Crystalluria and urinary tract abnormalities associated with indinavir

1 reference

12 December 2020

A randomized trial of the effect of ritonavir in maintaining quality of life in advanced HIV disease. Advanced HIV Disease Ritonavir Study Group

1 reference

12 December 2020

Fatal acute haemolysis in an AIDS patient treated with indinavir

1 reference

12 December 2020

Acute renal failure due to indinavir crystalluria and nephrolithiasis: report of two cases

1 reference

12 December 2020

Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. AIDS Clinical Trials Group Protocol 116B/117 Team and the Virology Committee Resistance Working Group

1 reference

12 December 2020

Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection

1 reference

12 December 2020

The effect of prescribed daily dose frequency on patient medication compliance

1 reference

12 December 2020

Determinants of compliance with antiretroviral therapy in patients with human immunodeficiency virus: prospective assessment with implications for enhancing compliance

1 reference

12 December 2020

10.2165/00002018-199920040-00002

Identifiers

DOI

1 reference

PubMed ID

10230580

Dimensions Publication ID

28 July 2017

0 references

1 reference

PubMed ID

10230580